February 20, 2022
Retrospective trial results inform utility of tivozanib in the real-world treatment of renal cell carcinoma.
February 19, 2022
Rates of progression-free survival at 3- and 4-year landmarks significantly improved with tivozanib vs sorafenib for relapsed or refractory RCC.
January 22, 2022
Using transarterial chemoembolization, lenvatinib, and PD-1 checkpoint blockade in patients with unresectable advanced hepatocellular carcinoma appears to be a safe and effective option.
December 28, 2021
Prognostic awareness impacted patients quality of life through psychosocial distress and symptoms burden.
December 13, 2021
Treatment with naratuximab emtansine and rituximab appeared to be well-tolerated with efficacious responses in a population of patients with B-cell non-Hodgkin lymphomas who were ineligible for stem cell transplant or CAR-T cell therapy.
December 12, 2021
Depression and anxiety notably impact how patients with hematologic malignancies view clinical studies.
September 19, 2021
Treatment [vic]-trastuzumab duocarmazine improved progression-free survival for patients with pretreated, metastatic HER2-positive breast cancer when compared with physician’s choice chemotherapy.
September 18, 2021
Those with advanced renal cell carcinoma whose disease was previously treated experienced long-lasting and robust overall survival following treatment with cabozantinib.
September 14, 2021
Progression-free survival lengths were different among patients with non-small cell lung cancer receiving sotorasib when stratified by genomic profile.
June 14, 2021
Close monitoring for neurologic toxicity resulted in no long-term effects in a patient cohort treated with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.